The FDA has expanded approval of Opzelura® (ruxolitinib) cream to include children ages 2-11 with mild to moderate eczema. It's the first treatment of its kind for this age group.

Read more about this non-steroidal option: https://bit.ly/4oNWNST

#EczemaRelief #PediatricEczema